Narrative
Lung cancer is the commonest cause of cancer-related mortality worldwide. Our research has driven pivotal trials leading to international licensing and routine clinical use globally of two new therapies, benefitting thousands of non-small cell lung cancer (NSCLC) patients worldwide and improving average survival from one year to four years. Osimertinib is licensed by the European Medicines Agency (EMA), the US Food and Drug Administration (FDA) and the Japanese Ministry of Health, Labour and Welfare (MHLW), recommended in European and US clinical guidance and available in >80 countries for treatment of epidermal growth factor receptor positive (EGFR+) NSCLC. Crizotinib is licensed by EMA and FDA, recommended in European and US clinical guidance and approved in >90 countries for treatment of anaplastic lymphoma kinase positive (ALK+) NSCLC.Impact date | 1 Aug 2013 → 31 Dec 2020 |
---|---|
Category of impact | Health and wellbeing, Economic |
Impact level | Adoption |
Research Beacons, Institutes and Platforms
- Cancer
- Manchester Cancer Research Centre
Documents & Links
Related content
-
Research output
-
Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component
Research output: Contribution to journal › Article › peer-review
-
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.
Research output: Contribution to journal › Article › peer-review
-
Final results of the large-scale multinational trial PROFILE 1005: Efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer
Research output: Contribution to journal › Article › peer-review
-
Validation of ROS1 by immunohistochemistry against fluorescent in situ hybridisation on cytology and small biopsy samples in a large teaching hospital
Research output: Contribution to journal › Article › peer-review
-
First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
Research output: Contribution to journal › Article › peer-review
-
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer
Research output: Contribution to journal › Article › peer-review
-
Patient-reported outcomes and quality of life in PROFILE 1007: a randomized trial of crizotinib compared with chemotherapy in previously treated patients with ALK-positive advanced non-small-cell lung cancer.
Research output: Contribution to journal › Article › peer-review
-
Impacts
-
Establishing the evidence for treatment to improve outcomes in patients with lung cancer
Impact: Health impacts